Kornimate/medical-research-clean huggingface dataset:
microcurrent therapy in the treatment of osteoarthritis of the knee

Conditions: Osteoarthritis,Knee

Summary: this study evaluates the effect of microcurrent therapy in the treatment of osteoarthritis of the knee. patients will be randomized to four groups: group 1 and 2 both will receive microcurrent therapy, but different currents will be used. group 3 will receive treatment with the microcurrent treatment apparatus, but without any current. group 4 will be a control group without specific interventions.

the objective of this randomized, controlled pilot study is to evaluate the effect of microcurrent therapy on pain and physical function in patients with osteoarthritis of the knee. the secondary objective is to compare the effects of different currents. patients will be randomized to four groups: group 1 and 2 both will receive microcurrent therapy, but different currents will be used. group 3 will receive treatment with the microcurrent treatment apparatus, but without any current. group 4 will be a control group without specific intervention. group 1, 2 and 3 will receive 10 sessions of treatment in a treatment phase of four weeks. assessments for group 1, 2, and 3 will be scheduled for screening (t0), at the first day of treatment (t1), at the end of treatment (t2) and three months after the end of treatment (t3). group 4 will be assessed at a screening visit t0, at t1, at t2 (approximately 21 days after t1), and at t3 (three months after t2). patients will be recruited based on the records of the clinic.

Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee * pain intensity \> 3 on the numerical rating scale (0-10) exclusion criteria: * knee arthroplasty * gravity * dermal irritation at the skin of the knee * carcinoma * known osteoarthritis grade 4 (kellgren and lawrence score)

Keywords: osteoarthritis microcurrent knee electrotherapy
risk and protective factors of children and adolescents who were hospitalized due to alcohol intoxication

Conditions: Alcohol Use Disorders

Summary: the aim of the study is to improve the prognosis of the development of alcohol consumption by considering a variety of biological, psychological and social risk and protective factors. therefore, young people who have been hospitalized due to acute alcohol intoxication within the past 5 to 12 years will be interviewed in order to assess aspects of healthy or impaired psychosocial development. the study will also include a control group of young adults who were in hospital due to other medical conditions. the identification of relevant cases will be based on medical records of several children's hospitals. these records will be analysed with regard to potential predictors of developmental hazards and protective factors.


Eligibility criteria:
experimental group: inclusion criteria: * male and female volunteers who were hospitalized due to acute alcohol intoxication from january 1, 2000 to december 31, 2006 * written informed consent by the subject * minimum age of 20 years exclusion criteria: * incapability to conduct interview control group: inclusion criteria: * male and female volunteers who were hospitalized due to other medical conditions but not acute alcohol intoxication from january 1, 2000 to december 31, 2006 * written informed consent by the subject * minimum age of 20 years exclusion criteria: * incapability to conduct interview
comparison of daily mometasone furoate nasal spray alone versus a combination with montelukast for treatment of chronic rhinosinusitis with asthma after functional endoscopic sinus surgery

Conditions: Sinusitis; Nasal Polyps; Asthma

Summary: 1. objectives. to compare the efficacy and the safety of mometasone furoate nasal spray (mfns; nasonex 200μg, daily) alone versus a combination with montelukast (singulair 10mg, daily) in chronic rhinosinusitis (crs) with asthma after functional endoscopic sinus surgery (fess) for improvement the clinical control of crs 2. the clinical hypotheses. the investigators hypothesize that postoperative combined montelukast and mfns can better improve clinical control of crs concomitant with asthma after fess compared with mfns alone. 3. study design this study is a 9-month randomized, open-label, controlled interventional study.

1. surgery plan * pre-operation: patients enrolled in the study will complete assessment and specimen collection on the first day, then followed by 1 week drug therapy with prednisone (30 mg once daily) and mfns(200ug, once daily). * fess: for patients with no surgical contraindications, fess will be performed. bilateral nasal cavities will be filled with swelling sponges postoperatively. the stuffing will be removed on postoperative day 2. the patients will be discharged on day 3 after surgery. * other treatment: all patients will receive nasal irrigation (normal saline 500 mg twice daily) from postoperative day 3 until day 30. asthma will be treated as the guidance of professors from the department of respiratory medicine in the investigators hospital. 2. drug treatment phase three days after the surgery (fess) described above, all patients will be assigned to the following two groups (30 patients each group) using random numbers generated by statistical software. * experimental group: montelukast (10mg, once daily) and mfns (200μg, once daily) for 6 months * control group: mfns (200μg, once daily) for 6 months 3. follow up after the 6-month drug treatment phase, there are still a 3-month follow-up. totally, there are 5 visits after fess surgery. * visit 1: baseline * visit 2： day 31 post-fess * visit 3: day 61 post-fess * visit 4: day 91 post-fess * visit 5: day 181 post-fess * visit 6: day 271 post-fess

Eligibility criteria:
inclusion criteria: 1. diagnosis of chronic rhinosinusitis according to european position paper of rhinosinusitis and nasal polyps 2007 2. diagnosis of asthma based on global initiative for asthma 2012 3. all patients should provide informed consent prior to the study and agree to follow-up appointments. exclusion criteria: 1. immunodeficiency diseases, history of head and/or facial trauma, cancer or organ transplant recipients. 2. pregnancy or lactation. 3. uncontrolled bronchial asthma. 4. acute respiratory tract infection within one month before the study. 5. use of leukotriene receptor antagonist within 3 months before the enrollment.

Keywords: chronic rhinosinusitis asthma montelukast surgery treatment outcomes
oral language in children with down syndrome

Conditions: Down Syndrome

Summary: the objective of this research is to verify the language of children with down syndrome concerning lexical, syntactic and semantic aspects using mlu. the hypothesis is that children with down syndrome will present low performance, regarding not only the quantitative measures as mlu-m, mlu-w, gm-1 and gm-2, but also regarding the qualitative aspects of their production, when compared to children with typical development.

one of the alternatives to observe and assess language development and language disorders is to analyze spontaneous language samples, which allos the identification of qualitative and quantitative aspects. the analysis involves the mlu-morphemes, mlu-words and words classes. all words produced are analyzed, including interjections, adverbs and adjectives.word classes with grammatical characteristics present lower averages, as prepositions and conjunctions. reference parameters are the ones of the spoken language. the objective assessment with qualitative and quantitative data may help the speech and language pathologist/therapist to determine therapeutic guidelines to each patient.

Eligibility criteria:
inclusion criteria: * genetic diagnosis of down syndrome * good health conditions * normal results on audiologic evaluation * pediatric and ear, nose and throat periodic check ups. * attend speech-language therapy at the speech language pathology laboratory in syndromes and sensorimotor deficits (slpl-ssd) of the school of medicine of the university of são paulo. exclusion criteria: * submission to long term hospitalizations due to heart diseases and major respiratory airway infections, that may interfere in the child's global development * presence of visual or auditory important deficits

Keywords: down syndrome mlu language development language assessment
ga-68-nodaga-mj9 compared to f-18-fch pet/ct for prostate cancer patients

Conditions: Prostate Cancer

Summary: prostate cancer patients for whom a f-18-fch pet/ct is indicated. ga-68-nodaga-mj9 is a new pet/ct radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging

patient with primary or relapsing prostate cancer for whom f-18-fch pet/ct is indicated will be proposed to participate to the present study. after signing the patient informed consent, both f-18-fch and ga-68-nodaga-mj9 pet/ct will be scheduled with a maximum 10 day-interval. no adverse events are expected.

Eligibility criteria:
inclusion criteria: * age : adult patients * karnofsky : ≥ 80% * patients with histologically proven prostate cancer for whom 18f-fluocholine pet/ct is indicated for primary cancer staging, or for recurrence with increase of blood psa. in order to provide a detection probability of 30% or more, a blood psa 0.5 ng / ml or more in post initial curative intent surgery will be required. * signed informed consent. exclusion criteria: * lack of discernment to sign the consent form * age \<18 years * patient under hormonal treatment

Keywords: prostate cancer primary recurrence f-18-fch pet/ct ga-68-nodaga-mj9 pet/ct
study to evaluate the efficacy and safety of telmisartan/amlodipine/rosuvastatin

Conditions: Dyslipidemia With Hypertension

Summary: to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.


Eligibility criteria:
inclusion criteria: * dyslipidemia with hypertesion * mssbp \< 180 mmhg * msdbp \< 110 mmhg * ldl-c ≤ 250 mg/dl * triglycerides \< 400 mg/dl exclusion criteria: * at visit 3, bp difference sbp ≥20mmhg or dbp ≥10mmhg * ck normal range ≥ 2 times * uncontrolled primary hypothyroidism(tsh normal range ≥ 1.5 times) * ast or alt ≥ 2 times * uncontrolled diabetes mellitus (hba1c≥9%) * clcr \< 30 ml/min/1.73m\^2 * k \> 5.5 meq/l * other exclusion applied
the effect of foot massage on blood pressure and anxiety levels in pregnants with hypertension

Conditions: Pre-Eclampsia; Gestational Hypertension; Chronic Hypertension With Pre-Eclampsia; Superimposed Pre-Eclampsia

Summary: this research was conducted as a prospective, experimental and randomised controlled research to determine the effect of foot massage applied to pregnant women with hypertension on blood pressure and anxiety levels.

the sample of the research a total of 80 pregnants, 40 interventions and 40 in the control groups, which were randomly selected from hypertension pregnant women who applied to health sciences university istanbul bakırköy doctor sadi konuk training and research hospital (beah). after the participants were given written and verbal information about the research, the intervention group received a foot massage for three days, 15 minutes on each foot, for a total of 30 minutes, while the control group did not receive foot massage. in the research; participant promotion form which contains questions about general health appearances and socio-demographic, gynecological and obstetric story, vital finding monitoring form to save blood pressure, pulse and breathing numbers restrained before and after foot massage, state and trade anxiety inventory (stai) which evaluates the level of anxiety, was used.

Eligibility criteria:
inclusion criteria: * pregnant women aged 18 years and over and diagnosed with hypertension during or before pregnancy were included in the study. exclusion criteria: * pregnant women who could not communicate in turkish were excluded from the study.

Keywords: gestational hypertension preeclampsia foot massage blood pressure anxiety
ginkgo biloba to improve short-term memory losses associated with electroconvulsive therapy (ect)

Conditions: Memory, Short-Term

Summary: electroconvulsive therapy (ect) is an effective treatment for severe or medication-resistant depression and other psychiatric disorders. a common side effect of ect is problems with short-term memory during treatment. this study will test whether taking ginkgo biloba (gb) prior to and during the course of ect will lessen the effects of ect on short-term memory.

ect is a safe and effective modern treatment for severe depression and other psychiatric conditions. an estimated 100,000 treatments occur per year in the united states. ect's most bothersome adverse effect is memory loss, with all patients receiving ect experiencing some degree of short-term cognitive impairment. at present there are no known effective pharmacologic treatments to prevent or improve ect-induced cognitive dysfunction. preliminary research has shown the herbal preparation gb aids cognitive function and memory in both patients with dementia and in normal volunteers. this study will investigate the utility and safety of gb to minimize the cognitive impairment typically associated with ect. participants in this study will be randomly assigned to receive either twice-daily gb or placebo. participants will begin taking gb or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of gb prior to ect. patients will undergo cognitive testing at specified intervals following ect. the final study visit will occur one week after a participant's final ect treatment.

Eligibility criteria:
inclusion criteria * dsm-iv diagnosis of major depressive episode, unipolar or bipolar, without psychotic features * receiving ect for depression * able to complete detailed neuropsychological testing exclusion criteria * psychotic symptoms * lifetime history of schizophrenia, schizoaffective disorder, or mental retardation * diagnosis of anxiety disorder, obsessive-compulsive disorder, or eating disorder within 1 year of study entry * delirium, dementia, or amnestic disorder * any active general medical condition or central nervous system disease which could affect cognition or response to treatment * diagnosis of active substance abuse or dependence within 6 months of study entry * ect within 6 months of study entry * known or suspected coagulation disorder * anticoagulation or antiplatelet medications, including warfarin, aspirin, clopidogrel, and ticlopidine * thiazide diuretics, selective serotonin reuptake inhibitors, trazodone, antipsychotic medications, herbal medications, or other nutritional supplements * pregnancy

Keywords: ect memory ginkgo biloba
interest of eye movement measurements in the comprehension of dry eyes symptoms

Conditions: Dry Eye Syndromes; Blinking

Summary: dry eye syndrome is a benign situation however its impact on patient's quality of live and on health system is not trivial. one problem is the lack of correlation between patient's symptoms and physical sign observed on slit lamp examination. eye blinking is a parameter of increased interest in this pathology particularly its frequency. to date no treatment of dry eye syndrome has a proven impact on eye blinking frequency. however recording of blinks has mostly been performed on short duration (3 to 5 minutes) and the distribution of intervals between 2 blinks is not gaussian but exponential. in this study, it is proposed to use modern eye-movement recorder to measure the blink frequency on longer duration (12 minutes) while reading on a screen computer and during a face-to-face interview before and after treatment of meibomian gland dysfunction responsible of moderate to severe dry eye syndrome.


Eligibility criteria:
inclusion criteria: * moderate to severe dry eye syndrome (ocular surface disease index\> 30) following a meibomian gland dysfunction * not yet properly treated for a meibomian gland dysfunction exclusion criteria: * history of other ophthalmological or neurological disease * pregnant or breastfeeding women * patient under 18 years old * patient under legal protection
prospective tumor response evaluation

Conditions: Hepatocellular Cancer; Metastatic Liver Cancer

Summary: the purpose of this study is to determine if mri imaging can detect genetic, proteomic, and metabolomic characteristics of liver tumors. the study also aims to determine if these imaging characteristics are correlated with clinical outcomes.

for each treatment arm, pre-procedural mri and post procedural mri will be obtained. pre-procedural biopsies will be obtained, if possible. pretreatment genetic expression, proteomic, or metabolomic patterns from the tumor samples will be assessed. imaging characteristics from tumors will be extracted using automated software-the study will apply a computational analysis system with the capability to extract and analyze imaging characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor characteristics. imaging findings will be correlated to clinical outcomes and genetic, proteomic, and metabolomic findings to determine association. imaging findings and genomic, proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes (time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).

Eligibility criteria:
inclusion criteria: * diagnosis or suspicion of primary or metastatic liver cancer deemed eligible for tace, y-90, percutaneous ablation, and /or electroporation. exclusion criteria: * any reason mri cannot be obtained.
testosterone and alendronate in hypogonadal men

Conditions: Hypogonadism; Osteopenia; Osteoporosis

Summary: this study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.


Eligibility criteria:
inclusion criteria: * male sex * age 60 or above * testosterone \<300 ng/dl * dxa t score \< -1 or frax score of 3% or greater for hip fracture or 20% or greater for major osteoporotic fracture exclusion criteria: * significant liver or kidney disease * elevated prolactin level * abnormal tsh * abnormal 25-vitamin d * psa \> 2.5 * history of malignancy * calcium \> 10.6 * alkaline phosphatase \> 150 * fracture within the last 6 months * history of acute urinary retention * hematocrit \ 50% * fracture within the past 6 months * american urological association bph symptom index \> 21 * sleep apnea * abnormalities of the esophagus which delay esophageal emptying * significant cardiopulmonary disease
a phase i trial of 61cu-nodaga-psma for patients with prostate cancer

Conditions: Prostate Adenocarcinoma

Summary: molecular imaging (mi) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. most current mi agents utilize fluorine 18 or gallium 68 as the positron emitter for pet imaging. however, these isotopes have short half-lives which limit the geographic distribution range of tracers made with these isotopes. copper 61 (61cu) has a 3.3 hour half-life, which would allow for far greater distribution range following radiotracer production. this phase i trial will test the safety and effectiveness of a novel mi radiotracer that uses 61cu as its positron emitting isotope and targets prostate specific membrane antigen (psma) for imaging prostate cancer. a successful trial will provide the ability to advance this novel 61cu-nodaga-psma radioisotope into phase ii trials, as well as open a new paradigm into the production of mi radioisotopes with 61cu.

this is a phase 1, non-randomized study. subjects will undergo imaging with 100-300 mbq (2.7-8.1 mci) of 61cu-nodaga-psma intravenously (iv), followed by pet/ct imaging 60 (+/- 10) minutes post radiotracer administration. this is a diagnostic imaging study. as the imaging agent will not have a treatment effect, efficacy evaluations that are standard in treatment protocols will not be performed. we expect to enroll 6-10 patients in the proposed study. the sample size is exploratory. for the primary objective of safety, side effects will be monitored the day of and the day following radiotracer administration. as the pet radiotracer used in this trial is given at a low, imaging dose, serious adverse events are not expected. if a single serious adverse event is identified, then the protocol will be held until reviewed by the irb. for the secondary objective of dosimetry, dosimetry will be calculated from pet/ct images and radioactive counts in blood samples by an experience medical physicist. for the secondary objective of effectiveness, the number of suspected psma-positive malignant lesions will be calculated in both the standard-of-care 18f-piflufolastat pet/ct and the experimental 61cu- psma pet/ct. positive lesions will be considered to be the foci greater than local background that are not physiologic/benign by location. the percentage of patients with any suspected psmapositive malignant lesions will be determined for each radiotracer.

Eligibility criteria:
inclusion criteria: 1. biopsy proven prostate adenocarcinoma 2. age ≥ 18 years 3. ecog 0 or 1 4. at least one site of psma-positive disease on a psma-targeted pet/ct performed within 30 days of trial recruitment 5. creatinine of ≤1.4 or creatinine clearance or ≥ 60 ml/minute. exclusion criteria: 1. known allergy/hypersensitivity to psma-targeted imaging agents 2. other active malignancy, other than the known prostate cancer

Keywords: psma pet/ct phase 1
validation of a simple and cost-effective nucleic acid test for hiv detection

Conditions: HIV; HIV Infections

Summary: validate a simple and cost-effective nucleic acid test for hiv detection in order to develop a rapid, highly sensitive and specific, one-stage test for the diagnosis of hiv infection. blood samples collected will be assayed using the biohelix corporation helicase-dependent amplification or the cepheid xpert hiv-1 quant assay. a false negative or false positive rate of \>1.0% would make this test unacceptable as a screening test for hiv viremia.


Eligibility criteria:
inclusion criteria: * current patient in the medical faculty associates infectious diseases (id) clinic with known hiv infection * suspected to be viremic at the time of their clinic visit based on history and/or current symptoms * able to provide informed consent * 18 years or older exclusion criteria: * patient unable to provide informed consent. * pregnancy

Keywords: hiv validation helicase-dependent amplification